Patents Assigned to Nanjing Immunophage BioTech Co., Ltd.
  • Compounds and their uses as MIF inhibitors
    Patent number: 11884682
    Abstract: The present invention provides compounds of Formula I which can be used as macrophage migration inhibitory factor (MIF) inhibitors; methods for the production of the compounds of the invention; pharmaceutical compositions comprising the compounds of the invention; as well as uses and methods for treating a disease mediated by MIF by administering the compounds of the invention.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: January 30, 2024
    Assignee: NANJING IMMUNOPHAGE BIOTECH CO., LTD.
    Inventors: Guohuang Fan, Kin Chiu Fong, Hongyu Yang, Jianfei Wang
  • Methods and compositions for targeting Tregs using CCR8 inhibitors
    Publication number: 20230038589
    Abstract: The present invention provides compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.
    Type: Application
    Filed: July 3, 2020
    Publication date: February 9, 2023
    Applicant: Nanjing Immunophage BioTech Co., Ltd.
    Inventors: Guohuang Fan, Hongyu Yang, Kin Chiu Fong, Jianfei Wang
  • ROR1 specific chimeric antigen receptors and their therapeutic applications
    Publication number: 20220356247
    Abstract: The present invention provides ROR1 specific chimeric antigen receptors (CAR) and their therapeutic use. The CAR comprises a signal peptide, a ROR1 antigen binding domain, a hinge, a transmembrane domain, a co-stimulatory domain and an intracellular signaling domain. The modified immune cells endowed with such CARs are suitable for treating malignancies such as cancer, chronic lymphocyte leukemia (CLL), and acute lymphocytic leukemia (ALL).
    Type: Application
    Filed: September 24, 2020
    Publication date: November 10, 2022
    Applicant: NANJING IMMUNOPHAGE BIOTECH CO.,LTD.
    Inventors: Guohuang FAN, Jianfei WANG
  • Anti-ROR1 antibodies and preparation method and uses thereof
    Publication number: 20220356246
    Abstract: The present invention relates to anti-ROR1 antibodies and to methods of using anti-ROR1 antibodies. The anti-ROR1 antibodies described herein are useful for the diagnosis and treatment of diseases, such as various cancers, associated with aberrant expression of ROR1.
    Type: Application
    Filed: September 24, 2020
    Publication date: November 10, 2022
    Applicant: NANJING IMMUNOPHAGE BIOTECH CO.,LTD.
    Inventors: Guohuang FAN, Jianfei WANG
  • Compounds as Inhibitors of Macrophage Migration Inhibitory Factor
    Publication number: 20220144838
    Abstract: The present invention provides compounds of Formula (I) shown below and their pharmaceutically acceptable salt, solvates, isomers, or prodrugs, as well as pharmaceutical compositions containing these compounds. Also provided by the invention is a method for treating a disorder mediated by macrophage migration inhibitory factor in a subject, comprising administering to the subject in need thereof a compound or a pharmaceutical composition of this invention.
    Type: Application
    Filed: March 13, 2020
    Publication date: May 12, 2022
    Applicant: NANJING IMMUNOPHAGE BIOTECH CO., LTD.
    Inventors: Kin Chiu FONG, Hongyu YANG, Ping DU, Jinfu YANG
  • COMPOUNDS AND THEIR USES AS MIF INHIBITORS
    Publication number: 20210403484
    Abstract: The present invention provides compounds of Formula I which can be used as macrophage migration inhibitory factor (MIF) inhibitors; methods for the production of the compounds of the invention; pharmaceutical compositions comprising the compounds of the invention; as well as uses and methods for treating a disease mediated by MIF by administering the compounds of the invention.
    Type: Application
    Filed: June 23, 2020
    Publication date: December 30, 2021
    Applicant: Nanjing Immunophage BioTech Co., Ltd.
    Inventors: Guohuang Fan, Kin Chiu Fong, Hongyu Yang, Jianfei Wang